Acumen represents thirteenth license partner
for ENHANZE®
Alzheimer's disease is a large and expanding
market opportunity
SAN
DIEGO, Nov. 6, 2023 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced a global
collaboration and non-exclusive license agreement with Acumen
Pharmaceuticals that provides Acumen access to Halozyme's
ENHANZE® drug delivery technology, a proprietary
recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid
subcutaneous drug delivery, for a single target. Acumen intends to
explore the potential use of ENHANZE® for ACU193,
Acumen's clinical-stage monoclonal antibody (mAb) candidate to
target Amyloid-β Oligomers (AβOs) for the treatment of early
Alzheimer's disease (AD).
Under the terms of the agreement, Acumen will make an upfront
payment to Halozyme, and potential future milestone payments
related to development progress, regulatory approvals, and sales
attainment. Halozyme will also be entitled to single digit
royalties on net sales of commercialized medicines with the
ENHANZE® technology.
This partnership presents an exceptional opportunity to provide
additional treatment options to patients with Alzheimer's disease.
According to the World Health Organization, over 55 million people
suffer from dementia worldwide, and Alzheimer's disease can be
attributed to 60-70% of cases.
Acumen reported positive Phase 1 results that demonstrated
ACU193 was generally well-tolerated with a compelling overall
safety profile, meeting the primary objective of its
first-in-human, randomized, double-blind, placebo-controlled study
in both single and multiple doses in patients with early AD. ACU193
has been granted Fast Track designation for the treatment of early
Alzheimer's disease by the U.S. Food and Drug Administration.
"Our collaboration with Acumen for ENHANZE reinforces our
commitment to provide innovative solutions to improve the patient
treatment experience, particularly for such a challenging disease
in a large patient population," said Dr. Helen Torley, president and chief executive
officer. "We share Acumen's view that the Alzheimer's disease
treatment paradigm is at a key inflection point with recent and
expected approvals paving a new path for treatment. We appreciate
the opportunity to enter this market and look forward to supporting
the development of ACU193 to emerge as a potential treatment of
choice."
This deal marks Halozyme's thirteenth global collaboration and
license partner for the ENHANZE® technology. These
collaborations cover more than 60 therapeutic targets and include
seven commercialized products to date.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® drug delivery technology with the proprietary
enzyme rHuPH20, Halozyme's commercially-validated solution is used
to facilitate the delivery of injected drugs and fluids in order to
reduce the treatment burden to patients. Having touched more than
700,000 patient lives in post-marketing use in seven commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Takeda, Pfizer, AbbVie,
Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen
Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED® and TLANDO® and partnered
commercial products and ongoing product development programs with
several pharmaceutical companies including Teva Pharmaceutical and
Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements including, without
limitation, statements concerning the possible activity, benefits
and attributes of ENHANZE®, the possible method of
action of ENHANZE®, its potential application to aid in
the dispersion and absorption of other injected therapeutic drugs
and statements concerning certain other potential benefits of
ENHANZE® including facilitating more rapid delivery and
administration of larger volumes of injectable medications through
subcutaneous delivery and potentially lowering the treatment burden
for patients. These forward-looking statements also include
statements regarding the product development and commercialization
efforts of Halozyme's ENHANZE® partner (including
the potential regulatory approval and launch of ENHANZE®
products as a result of such efforts and the potential future
market opportunity for such products) and Halozyme's potential
receipt of an upfront payment and payments associated with
achievement of certain development, regulatory and sales-based
milestones, and royalties on sales of commercialized products.
These forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue" and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including risks that the clinical trial results
may not be replicated, uncertainties concerning whether
development, regulatory and sales-based milestones will be
achieved, uncertainties concerning whether collaborative products
are ultimately developed, approved or commercialized and the
potential future market for such products, unexpected expenditures
and costs, unexpected results or delays in development and
regulatory review, unexpected regulatory approval requirements,
unexpected adverse events or patient outcomes and competitive
conditions. These and other factors that may result in differences
are discussed in greater detail in Halozyme's most recent
Annual and Quarterly Reports filed with the Securities and Exchange
Commission. Except as required by law, Halozyme undertakes no
duty to update forward-looking statements to reflect events after
the date of this release.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Dawn Schottlandt
Argot Partners
212-600-1902
Halozyme@argotpartners.com
Shannia Coley
CG Life
443-471-6830
scoley@cglife.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-and-acumen-pharmaceuticals-enter-global-collaboration-and-non-exclusive-license-agreement-for-the-enhanze-technology-in-alzheimers-disease-301978022.html
SOURCE Halozyme Therapeutics, Inc.